Indeed, in ALK(+) ALCL human cell lines, demethylating treatment, or ectopic expression of some microRNAs decreased protein target levels and sensitized the tumoral cells to chemotherapy (miR29a/Mcl1 [60]) potentiating the action of crizotinib (miR7-5p/Raf1 [61]) or disadvantaging crizotinib-resistant NPM-ALK(+) cell growth (miR150/MYB [44]). The gene discussed is ALK; the disease is anaplastic large cell lymphoma.